{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:47:45Z","timestamp":1765374465587,"version":"3.46.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004035","name":"Jordan University of Science and Technology","doi-asserted-by":"publisher","award":["134-2006"],"award-info":[{"award-number":["134-2006"]}],"id":[{"id":"10.13039\/501100004035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.toxrep.2025.102080","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:49:13Z","timestamp":1751428153000},"page":"102080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sildenafil effect on testosterone-induced prostate hypertrophy and relaxation of urinary bladder neck muscles"],"prefix":"10.1016","volume":"15","author":[{"given":"Qasim A.","family":"El-Dwairi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2808-5099","authenticated-orcid":false,"given":"Karem H.","family":"Alzoubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania","family":"Mahafdeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxrep.2025.102080_bib1","first-page":"224","article-title":"Erectile dysfunction, lower urinary tract symptoms, and quality of life in men above 50 years of age","volume":"74","author":"Guzm\u00e1n-Esquivel","year":"2021","journal-title":"Arch. Esp. Urol."},{"key":"10.1016\/j.toxrep.2025.102080_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12950-015-0099-7","article-title":"The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review","volume":"12","author":"Peixoto","year":"2015","journal-title":"J. Inflamm."},{"key":"10.1016\/j.toxrep.2025.102080_bib3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.juro.2008.10.025","article-title":"Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: The Krimpen Study","volume":"181","author":"Kok","year":"2009","journal-title":"J. Urol."},{"key":"10.1016\/j.toxrep.2025.102080_bib4","doi-asserted-by":"crossref","first-page":"e754","DOI":"10.1016\/S2666-7568(22)00213-6","article-title":"The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"3","author":"Awedew","year":"2022","journal-title":"Lancet Heal. Longev."},{"key":"10.1016\/j.toxrep.2025.102080_bib5","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1210\/en.2012-1431","article-title":"Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation","volume":"153","author":"Zenzmaier","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.toxrep.2025.102080_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.urology.2008.06.060","article-title":"Relaxant effects of sildenafil on the human isolated bladder neck","volume":"73","author":"Bittencourt","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.toxrep.2025.102080_bib7","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00345-019-02933-1","article-title":"Emerging drugs to target lower urinary tract symptomatology (LUTS)\/benign prostatic hyperplasia (BPH): focus on the prostate","volume":"38","author":"\u00dcckert","year":"2020","journal-title":"World J. Urol."},{"key":"10.1016\/j.toxrep.2025.102080_bib8","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1743-6109.2012.02661.x","article-title":"Effects of oral finasteride on erectile function in a rat model","volume":"9","author":"Zhang","year":"2012","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.toxrep.2025.102080_bib9","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.12688\/f1000research.160099.1","article-title":"Innovative approaches to benign prostatic hyperplasia management: Options beyond conventional treatment strategies","volume":"13","author":"Agu","year":"2024","journal-title":"F1000Research"},{"key":"10.1016\/j.toxrep.2025.102080_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jpm11060585","article-title":"The potential role of sildenafil in cancer management through epr augmentation","volume":"11","author":"Haider","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.toxrep.2025.102080_bib11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","article-title":"Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial","volume":"61","author":"Oelke","year":"2012","journal-title":"Eur. Urol."},{"key":"10.1016\/j.toxrep.2025.102080_bib12","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.eururo.2008.01.075","article-title":"A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"53","author":"Stief","year":"2008","journal-title":"Eur. Urol."},{"key":"10.1016\/j.toxrep.2025.102080_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/13543784.2024.2326023","article-title":"Early investigational agents for the treatment of benign prostatic hyperplasia","volume":"33","author":"Katsimperis","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.toxrep.2025.102080_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jnutbio.2017.12.009","article-title":"Obesity-induced mouse benign prostatic hyperplasia (BPH) is improved by treatment with resveratrol: Implication of oxidative stress, insulin sensitivity and neuronal growth factor","volume":"55","author":"Calmasini","year":"2018","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.toxrep.2025.102080_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/(SICI)1520-6777(1998)17:1<55::AID-NAU8>3.0.CO;2-C","article-title":"Chronology and urodynamic characterization of micturition in neurohormonally induced experimental prostate growth in the rat","volume":"17","author":"Lee","year":"1998","journal-title":"Neurourol. Urodyn. Off. J. Int. Cont. Soc."},{"key":"10.1016\/j.toxrep.2025.102080_bib16","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1172\/JCI109532","article-title":"Comparison of spontaneous and experimentally induced canine prostatic hyperplasia","volume":"64","author":"DeKlerk","year":"1979","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.toxrep.2025.102080_bib17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0302-2838(03)00377-4","article-title":"Pro-erectile effect of vardenafil: in vitro experiments in rabbits and in vivo comparison with sildenafil in rats","volume":"44","author":"Giuliano","year":"2003","journal-title":"Eur. Urol."},{"key":"10.1016\/j.toxrep.2025.102080_bib18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1177\/0960327111432505","article-title":"Evaluation of \u03b1-D-ribofuranose (D-ribose) toxicity after intravenous administration to rabbits","volume":"31","author":"Ismail","year":"2012","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.toxrep.2025.102080_bib19","first-page":"73","article-title":"Pharmacokinetic evaluation of D-ribose after oral and intravenous administration to healthy rabbits","author":"Alzoubi","year":"2018","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"10.1016\/j.toxrep.2025.102080_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11934-019-0917-1","article-title":"Benign prostatic hyperplasia and lower urinary tract symptoms: what is the role and significance of inflammation?","volume":"20","author":"Lloyd","year":"2019","journal-title":"Curr. Urol. Rep."},{"key":"10.1016\/j.toxrep.2025.102080_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.51585\/gjvr.2024.3.0108","article-title":"Comparative induction of benign prostate hyperplasia using testosterone propionate and estradiol benzoate in rabbit model","volume":"4","author":"Abubakar","year":"2024","journal-title":"Ger. J. Vet. Res."},{"key":"10.1016\/j.toxrep.2025.102080_bib22","first-page":"434","article-title":"Effect of sildenafil citrate in testosterone induced benign prostate hyperplasia rat model, Turkish","volume":"43","author":"\u00c7al\u0131\u015fkan","year":"2017","journal-title":"J. Urol."},{"key":"10.1016\/j.toxrep.2025.102080_bib23","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1743-6109.2006.00259.x","article-title":"Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction","volume":"3","author":"Mulhall","year":"2006","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.toxrep.2025.102080_bib24","first-page":"163","article-title":"Re: PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS","volume":"192","author":"Kaplan","year":"2014","journal-title":"J. Urol."},{"key":"10.1016\/j.toxrep.2025.102080_bib25","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/pros.22686","article-title":"PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS","volume":"73","author":"Vignozzi","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.toxrep.2025.102080_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ijir.2010.26","article-title":"The effectiveness of sildenafil citrate in patients with erectile dysfunction and lower urinary system symptoms and the significance of asymptomatic inflammatory prostatitis","volume":"22","author":"Eryildirim","year":"2010","journal-title":"Int. J. Impot. Res."},{"key":"10.1016\/j.toxrep.2025.102080_bib27","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/iju.15046","article-title":"PDE5 inhibitors and male reproduction: Is there a place for PDE5 inhibitors in infertility clinics or andrology laboratories?","volume":"29","author":"Dimitriadis","year":"2022","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.toxrep.2025.102080_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mehy.2006.11.040","article-title":"Mechanism of phosphodiesterase 5 inhibitor relief of prostatitis symptoms","volume":"69","author":"Grimsley","year":"2007","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.toxrep.2025.102080_bib29","article-title":"Nitric oxide in the lower urinary tract: Physiological and pathological implications","volume":"85","author":"Mumtaz","year":"2000","journal-title":"BJU Int."}],"container-title":["Toxicology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750025001982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750025001982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:47:56Z","timestamp":1765370876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214750025001982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"alternative-id":["S2214750025001982"],"URL":"https:\/\/doi.org\/10.1016\/j.toxrep.2025.102080","relation":{},"ISSN":["2214-7500"],"issn-type":[{"type":"print","value":"2214-7500"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sildenafil effect on testosterone-induced prostate hypertrophy and relaxation of urinary bladder neck muscles","name":"articletitle","label":"Article Title"},{"value":"Toxicology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxrep.2025.102080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102080"}}